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Abstract 
 
Background: Contact allergy is a common condition and can severely interfere with daily life 
or professional activities. Due to changes in exposures, a consequence of introduction of 
new substances, new products or formulations, and regulatory intervention, the spectrum of 
contact sensitisation changes.  
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Objective: To evaluate the current spectrum of contact allergy to allergens present in the 
European baseline series (EBS) across Europe.  
Methods: Retrospective analysis of data collected by the European Surveillance System on 
Contact Allergies (ESSCA, www.essca-dc.org) in consecutively patch tested patients, 
2013/14, in 46 departments in 12 European countries.  
Results: Altogether, 31689 patients were included in the analysis. Compared to a similar 
analysis in 2004, the prevalence of contact allergy to methylisothiazolinone went up to 
around 20% in several departments. In comparison, contact allergy to the metals nickel, 
cobalt and chromium remained largely stable, at 18.1, 5.9 and 3.2%, respectively, similar to 
mostly unchanged prevalences with fragrance mix I, II and Myroxylon pereirae (Balsam of 
Peru) at 7.3, 3.8 and 5.3%, respectively. In the subgroup of departments diagnosing (mainly) 
patients with occupational contact dermatitis, the prevalence of work-related contact 
allergies such as to epoxy resin or rubber additives was increased, compared to general 
dermatology departments.  
Conclusion: Continuous surveillance of contact allergy based on network data offers the 
identification of time trends or persisting problems, and thus enables focussing in-depth 
research (subgroup analyses, exposure analysis) on areas where it is needed. 
 
Key words: Clinical surveillance; contact allergy; patch testing; sensitisation. 
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Introduction 
 
Contact sensitisation (CS) in terms of a delayed-type hypersensitivity can be directed to a 
multitude of low molecular-weight substances, i.e., natural or synthetic haptens. 
Sensitisation is diagnosed by patch testing, for which standards have recently been 
published by the European Society of Contact Dermatitis (ESCD)(1). The frequency of CS has 
been examined in a population-based study in 5 European countries conducted between 
2008 and 2011. In this study, 27.0% of the representative patch tested sample (n=3119) had 
at least one positive reaction to an allergen of the European baseline series (EBS)(2). As 
population-based epidemiological studies are valuable, but infrequently performed, 
continuous epidemiological surveillance of CS relies on clinical networks collecting routine 
patch test data. The aim is to provide a timely public health alert concerning increasing 
trends or persisting problems, or a feed-back regarding the success of preventive action, as 
indicated.  
 
As one such network, the European Surveillance System on Contact Allergies (ESSCA, 
www.essca-dc.org, last accessed 14 February 2017), which has been operative since 2002, 
presently links departments of dermatology in 12 European countries and collects data from 
about 15000 patients per year. Several analyses of patch test results with the EBS in patients 
patch tested for suspected CS in the participating departments have been published since 
2002, e.g.(3), lately also including more in-depth views on different groups of allergens from 
the EBS, such as fragrances(4), metals(5), preservatives(6), rubber chemicals(7)(8) or topical 
therapeutics and excipients(9). Following the main approach of providing a concise overview 
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of the full range of EBS allergens as in(3), we herewith present an update of the data 
collection period 2013/14. To enable easier comparisons with previous results obtained in 
2004, published in this journal(3), we follow a largely similar presentation. 
 
Methods 
 
The retrospective analysis is based on routine clinical data collected by the ESSCA network, 
which has already been described in previous publications(3). Briefly, clinical and 
demographic data, along with patch test results, of all patients patch tested in the 
departments participating in ESSCA for suspected allergic contact dermatitis due to various 
potential exposures are documented electronically in the local departments. These use 
diverse data capture software and partly the multilingual software WinAlldat/ESSCA 
provided by ESSCA(10). Standardised patch testing follows international 
recommendations(1). The anonymised data delivered by the participants are pooled in the 
ESSCA data centre in Erlangen for further analysis(11), using R (version 3.2.3) software 
(www.r-project.org, last accessed 14 February 2017). Considering the fact that all individual 
identifiers were removed from the collected data, and no quasi-unique profiles, but only 
aggregated results are reported, such pooled analysis is deemed compliant with data 
protection requirements. Pertinent guidelines for the statistical analysis of patch test 
data(12) (13) were considered. The maximum patch test reaction between day 3 and day 5 
(inclusive) was aggregated as patch test outcome. Reactions designated as either +, ++ or 
+++ were classified as positive (allergic), the remainder as non-allergic. The study period was 
01/2013 to 12/2014, including 12 European countries and, in total, 46 departments.  
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Test results with the European baseline series (EBS) valid in the study period, during which 
methylisothiazolinone (MI) 2000 ppm aq. had been added, and the recommended test 
concentration of methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI) had been 
increased from 100 to 200 ppm, and of formaldehyde from 1 to 2%(14), were analysed. 
Altogether, 31689 patients have been registered who were tested with the EBS and were 
read at least between day (D) 3 and D5. The TRUE Test® employing a hydrocellulose matrix 
for the haptens instead of petrolatum or water had been used in a relatively small number of 
patients, namely n=1214, while the vast majority of patients was tested with petrolatum- 
and water-based haptens and investigator-loaded chambers systems, respectively. 
Moreover, 2 German departments use a 1 day patch test exposure, applied to n=948 
patients. As in previous analyses the impact of these variations of standard technique has 
been found to be limited, except for, e.g., fragrance mix I as tested with the TRUE Test®(15) , 
the results have all been pooled, but were annotated in case extreme values were observed 
related to one of these factors.  
 
Results 
 
In the years 2013 and 2014, altogether 31689 patients have been patch tested in the 46 
European departments. The three departments contributing the lowest number of patients 
were SI-07 (n=49), ES-05 (n=121) and ES-06 (n=129). On the other end, the three 
departments contributing the largest number of patients were NL-02 (n=2019), DK-01 
(n=2139) and UK-99 (n=2503). A wide variation of the proportion of male patients and 
patients aged 40 or above can be observed between departments and also between 
countries, as shown in Fig. 1 a and b. For instance, the average age of patients patch tested 
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in German department is higher than in UK departments. Table 1 provides an overview of 
the characteristics of the patients of the participating departments according to the 
MOAHLFAP index(16). For this purpose, specialised departments were grouped, and analysis 
stratified for (i) general dermatology departments (n=39), (ii) occupational departments 
(n=6, including the FIOH, Helsinki, FI, Osnabrück and Heidelberg, DE, Trieste, IT, Łodz, PL, and 
Cádiz, ES), and (iii) the one purely paediatric department in Padova, IT. The patient 
characteristics show considerable variation, also within the two subgroups of general and 
occupational departments, with a characteristic predominance of male, occupational and 
hand dermatitis patients in the latter subgroup. As an extension of the MOAHLFAP index, the 
proportion of patients with dermatitis of the trunk and generalised dermatitis, respectively, 
have been analysed, revealing a large variation between departments and, moreover, a 
considerable overall proportion of these patterns of dermatitis. 
 
Patch test results with the EBS in the 39 general dermatology departments are shown in 
Table 2, together with the results of the one paediatric dermatology department in Padova, 
Italy. Overall crude and standardised results, as well as minimum and maximum 
standardised prevalences, following the approach inError! Reference source not found. are presented, 
also using the same ranking by decreasing standardised sensitisation prevalence. Where 
applicable, results are stratified for different test concentrations as partly used. The 
considerable variation between departments, partly also within one country, is reflected by 
the fact that all allergens of the EBS elicited some positive reactions in some departments, 
while in other departments, they have been entirely negative.  
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Concerning the 6 departments specialised in occupational dermatology the results with 
the EBS are shown in Table 3. Comparing the sensitisation prevalences to EBS allergens 
between these departments, variation related to differing age- and sex-structure (Table 1) 
should largely have been eliminated by using age- and sex-standardised(17)  prevalences, as 
in the general comparison. Hence, differences in the relative frequency of contact allergies 
are most likely due to other factors, partly reflected by the other MOAHLFAP factors (Table 
1) as well as presumably unmeasured effects, see discussion.  
 
Discussion 
 
The present analysis addresses the current spectrum of contact allergy across 12 European 
countries, represented by a range of 1-8 departments, 10 years after a previous analysis 
published in the JEADV. The scope of participating countries has remained constant, with the 
addition of Slovenia since 2009, and limited changes of departments participating in ESSCA 
were in effect (e.g., St. John’s, London, joining, and several UK departments involuntarily 
dropping out due to software problems). Therefore, a comparison between the 2 sampling 
periods is an interesting option for discussing results.  
 
First, the patient population characteristics, which are strongly associated with the spectrum 
of contact allergy found in a department(17), are of interest. The MOAHLFA index, recently 
expanded by additionally considering the percentage of patients positive to at least one 
baseline series allergen(16)  has proven useful for a basic description of the patients patch 
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tested in a certain department, or other defined subgroups. Compared to the earlier period 
(2004), a slight decrease in the percentage of male patients and particularly in the 
percentage of patients with occupational dermatitis is noted in the ‘general’ dermatology 
departments. In contrast, the proportion of patients with atopic dermatitis (in the UK 
traditionally comprising atopic patients in general) has increased considerably, although the 
age structure has shifted towards older age – with marked differences (Figure 1b). It can only 
be speculated whether such increase is a true reflection of an increase of atopic diseases, 
including atopic eczema, or merely related to the slight changes in contributing 
departments. Interesting, but difficult to explain, is a considerable decrease in the 
percentage of hand and leg dermatitis, while the percentage of patients with face dermatitis 
remained largely constant, possibly driven by the epidemic of methylisothiazolinone (MI) 
contact allergy (18) often affecting the face due to cosmetic exposures (19). At least the 
decrease of contact allergy to topical drugs (and thus e.g. of leg dermatitis) is consistent with 
findings from other departments (20).  Inter-departmental differences in the percentage of 
patients with at least one positive reaction to the (European) baseline series have been 
noted throughout all ESSCA analyses, including(3). In this analysis, we restricted the set of 
baseline series allergens to those present in the EBS (14) to increase comparability. Due to 
the fact that some national groups and departments, respectively, choose to omit certain 
allergens of the EBS in their baseline series recommendations, the overall yield in these 
departments will evidently be somewhat lower; further aspects, also including differing 
selection processes, health systems and methodological issues, have been analysed and 
discussed in detail in (21). Focussing on the departments specialised in occupational 
dermatology, a striking variation of the percentage of patients eventually diagnosed with 
‘occupational contact dermatitis’ has been noted before (3) The observation of a lesser 
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proportion of ‘occupational contact dermatitis’ in a specialised department than in one 
(albeit small) general department (Trieste vs. Léon; see Table 1) is puzzling. Indeed, varying 
definitions of work-related skin disease and, in particular, occupational contact dermatitis 
(22) may be one reason for such diversity, which certainly hampers meaningful international 
comparisons of all aspects of occupational contact dermatitis and allergy, respectively (23).  
 
The overall (crude or standardised) prevalence of contact allergies to the EBS allergens are 
lower for all 3 metals among the ‘general’ departments, compared to 2004. Interestingly, the 
2009-12 analysis shows age- and sex-adjusted sensitisation frequencies in-between the 
current and the 2004 results(5). However, it seems premature to conclude on a downward 
trend; instead, more detailed analyses seem necessary. These can be combined with 
exposure assessment, which is greatly aided by the availability of ‘spot test’ not only for 
nickel release (the well-known dimethyl glyoxime test), but also for cobalt (24) and 
chromium (25) release. In contrast to metals, the sensitisation prevalence for the fragrance 
screening markers of the EBS, namely fragrance mix I and Myroxylon pereirae (balsam of 
Peru), remained largely unchanged. It should be noted that fragrance mix II and its main 
allergen hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC) had only been introduced to 
improve the diagnosis of fragrance contact allergy (26) several years after the 2004 data 
analysis.  
 
Of particular interest are the preservatives, due to the cycles of increasing exposure to a new 
preservative by broad marketing, increasing awareness of sensitising potential through case 
reports, systematic patch testing and awareness of yet another epidemic, and eventual 
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regulation of exposure, either in terms of a ban, or limited use concentrations (27). Indeed, 
following the ban of methyldibromo glutatonitrile (MDBGN) in 2004 for leave-on and 2008 
for rinse-off cosmetics, the sensitisation prevalence observed now is roughly halved. 
Ongoing exposure by other, non-cosmetic products, and new sensitisation still occurs (6). 
The latest epidemic of contact allergy to preservatives has been observed to 
methylisothiazolinone (MI) (18). The steep increase and the high frequency of MI and 
MCI/MI contact allergy observed in this study as well as in numerous previous studies from 
European countries underline the urgency of the regulatory measures to reduce exposure to 
MI and MCI/MI both in consumers and in an occupational context (18). The importance of 
MI is visible in the results presented in terms of sensitisation prevalences > 7% to the three 
different test concentrations used – this is an extraordinarily high contact allergy prevalence 
in consecutive patients and has, to the best of our knowledge, not previously been observed 
for a preservative. Interestingly, the 3 different patch test concentrations used, i.e., 200 
ppm, 500 ppm and 2000 ppm (0.2%), all in water (aq.), have a very similar yield of positive 
patch test reactions. However, a formal comparison of diagnostic performance, ideally 
employing an independent gold standard such as specific history or use-related verification 
tests, is not possible based on our data, as different sets of patients had been tested. The 
same holds true for methylchloroisothiazolinone (MCI)/MI and formaldehyde, the 
concentration of which had been increased to 200 ppm aq. and 2% aq., respectively, to 
enhance diagnostic accuracy. Curiously, the overall yield is very similar, if perhaps showing a 
slightly higher percentage of positive reactions for the higher test concentration in case of 
formaldehyde, but, again, a valid comparison is not possible. It should be mentioned that, 
according to the ESCD patch test guideline (1), water-based allergens should be dosed with a 
micropipette, to avoid overdosing with subsequent irritation or even an increased risk of 
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active sensitisation. Although currently there is only low exposure to formaldehyde in 
cosmetics, technical fluids, paints and lacquers, formaldehyde-releasing preservatives such 
as imidazolidinyl or diazolidinyl urea, DMDM hydantoin, quaternium 15 (the only one 
included in the EBS), bronopol (2-bromo-2-nitropropane-1,3-diol) and others contribute to a 
relevant exposure to free formaldehyde (6) , which makes a reliable diagnosis of 
formaldehyde contact allergy ever so important. Parabens are a widely-used class of 
preservatives (28). However, in many cosmetic products they have been replaced with other 
preservatives due to alleged ‘endocrine disrupting’ properties – such replacement by MI can 
actually be regarded as one of the driving forces of the MI contact allergy epidemic just 
discussed. The lower sensitisation prevalence in the present material [0.5% (95%CI: 0.4-
0.6%) vs. 1.0% (95%CI: 0.8-1.2%) in 2004] is possibly a reflection of such lesser usage of 
parabens.  
 
Compared to 2004, standardised sensitisation prevalences to primin in Europe dropped 
considerably from 0.78% (95% CI 0.6-1.0%) to 0.2 % (95%CI 0.2-0.3%). This is likely due to the 
availability of primin-free cultivars of Primula obconica H. in Europe since 2000 (29). 
Concerning primin, no difference in sensitization frequency is seen between departments 
specialized in occupational dermatology compared to general dermatology departments, 
neither in 2004 nor in 2013/14. Therefore sensitisation to this plant allergen is probably not 
often related to occupational exposure. Concerning sequiterpenlactone mix, the frequency 
of sensitization did not change, with 0.73% (95%CI 0.5-0.9%) in 2004 and 0.7% (95%CI 0.6-
0.8%) in 2013/14, respectively. However, to identify contact allergy to Compositae, 
additional testing of the Compositae mix or other relevant Compositae extracts is 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
recommended, which provide a higher overall detection of contact allergy to plants of the 
Compositae family (30). The sensitisation prevalence of colophonium, a resin from conifers, 
a fragrance allergy marker in a broad sense (31) and also used in adhesives, has remained 
largely stable.  
 
Several active drug components are part of the EBS. Contact allergy to neomycin sulfate 
declined significantly from 2.1% (95%CI: 1.8-2.3%) in 2004 to 1.2% (95% CI: 1.1-1.4%), which 
may reflect an overall declining exposure and sensitisation. This had actually been identified 
in Germany (32)  and thus, further motivated by the notion of previous exposure to the few 
neomycin-containing drugs being relatively easy to identify (for history-based aimed testing), 
the German Contact Dermatitis Group had removed neomycin from its baseline series many 
years ago. However, in other countries, with more wide-spread exposure, possibly by ‘over-
the-counter’ (OTC) availability, as in the USA, neomycin sulfate may still be worthwhile to 
test (33). Two corticosteroid screening allergens are used in the EBS, namely, tixocortol 
pivalate 0.1% pet. and budesonide 0.01% pet. Both corticosteroids are also frequently tested 
in a 10-fold higher concentration, and there is an on-going debate both on how to 
adequately patch test these difficult allergens (34) and moreover also on how to classify 
corticosteroid contact allergy (35). Clioquinol nowadays does not appear to be an important 
topical drug contact allergen and does not warrant inclusion in the EBS any longer, for which 
normally a reaction frequency of above 0.5 or 1% in consecutive patients is considered as 
inclusion criterion (36) – in case of clioquinol, the upper 95% CI is 0.4% and thus falls short of 
this conventional threshold. Of note, this low prevalence of sensitisation has been stable for 
at least a decade (3). Benzocaine is an ester type local anaesthetic used in a range of topical 
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preparations, some available OTC. Despite this, the reaction prevalence is low in the present 
results, and even lower than in the previous analysis of 2004 data [0.6% (95%CI: 0.5-0.7%) vs. 
1.1% (95%CI: 0.8-1.4%)]. The use of a suitable mix of ‘caines’, including cinchocaine (syn; 
dibucaine), as a possible replacement of benzocaine in the EBS should be considered, in 
particular, as benzocaine as  screening marker has been found to miss 70% of contact 
allergies to local anaesthetics (37).  
 
The one excipient included in the EBS, beyond preservatives and fragrances already 
discussed, is lanolin alcohol, showing a stable prevalence of sensitisation of around 2%. 
Lanolin (wool alcohols) contact allergy has been somewhat provocatively called a “myth” in 
the past (38) and mild irritant patch test reactions are certainly possible, as with other 
emulsifiers. However, lanolin alcohol must nevertheless be regarded as important allergen 
to screen with, particularly in leg dermatitis patients. Positive reactions should carefully be 
evaluated, e.g. involving repeated open application or provocative use testing with lanolin 
alcohol-containing products, to ascertain clinical relevance of a positive patch test reaction. 
Recently, it has been pointed out that in children and adolescents with atopic eczema also 
the lanolin alcohol derivative Amerchol L101 (which has no own INCI name) commonly 
caused positive patch test reactions (39). Therefore, it may be worthwhile to further 
examine the most suitable patch test preparation.  
 
A number of allergens of the EBS are more or less associated with occupational exposure 
(40). Among these, p-phenylenediamine (PPD) – evidently also important for hair dye self-
users and hairdressers’ clients – shows some overall decline [3.2% (95% CI: 3.0-3.4% vs. 4.1% 
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(95%CI: 3.7-4.5%) in 2004]. This may be the first indication of a reduction of use of PPD in 
oxidative hair dyes witnessed, e.g., in Germany, in terms of a replacement with modified PPD 
derivatives (41). Unfortunately, exposure to very high skin doses of PPD is still occurring via 
so-called ‘temporary henna tattoos’, as extensively reviewed in (42). Rubber allergens are 
quite prominent in the EBS, with 3 mixes and one singular allergen, and sensitisation is often, 
but not always, occupation-related. The present data show some decline of contact allergy 
to thiuram mix [1.9% (95% CI: 1.8-2.1%) vs. 2.6% (95%CI: 2.3-2.9%) in 2004], while the other 
rubber additives remained largely stable. It has to be noted that diagnostic work-up of 
patients with suspected rubber-related allergic contact dermatitis should not solely rely on 
these 4 EBS allergens, because as many as 40% with eventually diagnosed contact allergy to 
rubber additives will be missed if further rubber additives and mix breakdowns are not 
additionally tested (7). An in-depth discussion of adequate patch test diagnosis of rubber 
contact allergy is found in a recent review (43). The prevalence of contact allergy to p-tert 
butylphenol formaldehyde resin in consecutive patients halved, compared to 2004, which 
may be indicative of a reduced importance of this adhesive mainly used in footwear; 
however, reliable exposure information is, as in many fields, lacking.  
 
In conclusion, the comparison between 2004 and 2013/14 demonstrated the remarkable 
increase of contact allergy to methylisothiazolinone and, related, to MCI/MI. Other allergens, 
including fragrances and metals, remained largely stable, while a substantial proportion of 
EBS allergens showed a decreasing trend. However, as the sample of European departments 
is only partly identical with the 2004 analysis, such downward trend should probably not be 
interpreted as an indication of a decreasing importance of the respective contact allergens; 
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further in-depth analyses such as (44)  appear necessary to draw firmer conclusions. Based 
on the present results, and on previous observations, it is suggested to omit the following 
allergens from the EBS, or possibly replace them with more suitable test preparations: 
 Clioquinol 
 Primin 
 Benzocaine, to be replaced with a suitable caine mix 
Figure 1: Departmental and national variation of the percentage of male patients (a) and of 
patients age 40 and above (b).  
 
Table 1: Characteristics of (patients of) the departments participating in the ESSCA network 
2013/14, including the MOAHLFA-P index (16), stratified for non-specialised departments 
(n=39), occupational dermatology departments (n=6) and the paediatric dermatology 
department in Padova, Italy. The ‘%’ column indicates the average of the respective group. 
Avg., average; min, minium; max, maximum. 
 
  Non-specialised Occupational Paediatric 
  Avg. 
% 
min. % max. % Avg. % min. % max. % % 
 Male M 31.3 21.5 (Kaunas, 
LT) 
42.9 
(Ljubljana/Clinic, 
SI) 
43.3 27.1 
(Łodz, PL) 
58.5 (Heidelberg, 
DE) 
42.2 
Occupational 
dermatitis 
O 10.3 1.3 
(Middlesbrough
, UK) 
43.4 (León, ES) 44.6 11.2 
(Trieste, 
IT) 
76.8 (Osnabrück, 
DE) 
0 
Atopic 
dermatitis 
A 23.3 8.8 (León, ES) 44.3 (Oxford, UK) 28.1 8.3 
(Trieste, 
IT) 
54.2 (Osnabrück, 
DE) 
55.9 
Hand 
dermatitis 
H 21 9.1 (Napoli, IT) 42.5 (Vigo, ES) 61.6 24.2 
(Trieste, 
IT) 
89.2 (Osnabrück, 
DE) 
16.4 
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Leg dermatitis L 4.1 1.3 (Napoli, IT) 14.8 (Dresden, DE) 2.0 0.6 
(Osnabrü
ck, 
Heidelber
g, DE) 
3.9 (Trieste, IT) 11.3 
Face dermatitis F 17 3 (Napoli, IT) 37.6 (Oxford, UK) 6.3 1.5 
(Heidelbe
rg, DE) 
17.2 (Łodz, PL) 19.3 
Age 40+ A 60.2 42.9 
(Ljubljana/Clinic
, SI) 
77.4 (Kiel, DE) 63.8 51.7 
(Helsinki, 
FI) 
68.8 (Heidelberg, 
DE) 
0 
at least 1 pos. 
reaction 
P 44.1 29.9 (Celje, SI) 60.5 (León, ES) 41.1 32.2 
(Osnabrü
ck, DE) 
53.7 (Łodz, PL) 21.9 
Trunk 
dermatitis 
 7.4 0 (Krakow, PL) 37.9 
(Barcelona/IMAS, 
ES) 
3.1 0.3 
(Osnabrü
ck, DE) 
8.4 (Łodz, PL) 9.0 
Generalised 
dermatitis 
 9.1 0 (León, 
Krakow) 
26.3 (London, UK) 7.8 2.0 
(Osnabrü
ck, DE) 
18.5 (Heidelberg, 
DE) 
7.1 
   
For the ‘OAHL’ characteristics data was not recorded in the Slovenian departments. The ‘P’ 
percentage refers to positive reactions only to allergens of the EBS, not to possible 
departmental or national extensions thereof.  
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Table 2: Patch test results with the European baseline series valid during the study period (14), with, however, partly diverging patch test 
concentrations, obtained in non-specialised ESSCA departments. At the very right, results in the Padova department of paediatric dermatology 
as crude % positives ( = 374 to 376). The maximum reading between day (D)3 and D5 (inclusive) was considered. stand., standardised for age 
and sex (17); allergens in decreasing order of standardised prevalences. nr (test), number of patients tested (in all general and the one 
paediatric departments). 
  
 Conc. nr crude stand. 95% minimum maximum paed. dept. 
Hapten % (test) %(pos) %(pos.) CI %(pos.) %(pos.) crude % 
Nickel sulfate 5 28109 18.7 18.1 17.7-18.6 7.6 (4-11.3) Dortmund (DE) 35.3 (29.2-41.3) León (ES)
TT
 9.1 (6.4–12.5) 
Methylisothiazolinone* 0.02 4383 10.7 10.2 9.3-11.1 6.9 (5.7-8.1) Krakow (PL) 19.6 (15-24.3) 
Madrid/Princesa (ES) 
– 
Methylisothiazolinone* 0.05 6713 7.4 7.3 6.6-7.9 0.6 (0-1.5) Graz (AT) 19.9 (9.8-29.9) Murcia (ES) – 
Methylisothiazolinone* 0.2 6677 7.8 7.6 6.9-8.2 6.4 (5.1-7.8) Newport (UK) 20.8 (10.7-30.9) Murcia (ES) – 
Fragrance mix I 8 27892 7.8 7.3 7-7.6 0 (0-2.5) Aarau (CH) 16 (12.3-19.7) Kiel (DE)
D1
 0 (0–1) 
MCI/MI* 0.01 19790 7.4 7.3 6.9-7.7 1 (0.3-1.7) Celje (SI) 17.9 (13.4-22.3) 
Madrid/Princesa (ES)
TT
 
1.9 (0.8–3.8) 
MCI/MI* 0.02 9722 7.7 7.3 6.8-7.9 3.5 (2.7-4.3) Copenhagen (DK) 15.8 (11.4-20.1) Alicante 
(ES) 
– 
Cobalt chloride 1 27873 5.9 5.9 5.6-6.2 0 (0-45.1) Napoli (IT) 13.8 (11.5-16) Poznan (PL) 8.8 (6.1–12.1) 
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Myroxolon pereirae (Balsam of Peru) 25 27274 5.7 5.3 5-5.6 0.7 (0-1.7) León (ES)
TT
 13.3 (10.3-16.4) Graz (AT) 0.5 (0.1–1.9) 
Fragrance mix II 14 28145 4 3.8 3.6-4 0.4 (0-1.1) Middlesbrough (UK) 9.1 (5.3-12.9) Göttingen 
(DE) 
– 
Potassium dichromate 0.5 26390 3.3 3.2 3-3.4 0 (0-2.5) Aarau (CH) 11.4 (9.3-13.6) Poznan (PL) 4.5 (2.7–7.1) 
p-Phenylenediamine 1 24931 3.3 3.2 3-3.4 1.4 (0.3-2.4) Vigo (ES) 6.1 (4.3-7.8) Napoli (IT) 0 (0–1) 
Colophonium 20 26991 2.9 2.8 2.6-3 0.3 (0-0.6) Genova (IT) 5.2 (2.9-7.6) Kiel (DE)
D1
 0 (0–1) 
MDBGN 0.2 5498 2.5 2.2 1.8-2.6 1.4 (0-3) Dortmund (DE) 3.7 (0.9-6.6) Aarau (CH) – 
MDBGN 0.3 13831 2 1.9 1.6-2.1 0 (0-1.3) Middlesbrough (UK) 6.1 (5.1-7.1) Amsterdam VU 
(NL) 
– 
MDBGN 0.5 8246 2.4 2.2 1.9-2.5 0.4 (0-1.2) León (ES)
TT
 7.5 (0.2-14.7) 
Ljubljana/Clinic (SI) 
– 
Lanolin alcohol 30 26178 1.9 1.9 1.7-2.1 0 (several depts.) 6.5 (4-8.9) Erlangen (DE) 0.5 (0.1–1.9) 
Thiuram mix 1 28610 2 1.9 1.8-2.1 0.4 (0-1.2) León (ES)
TT
 4.5 (2.5-6.5) Erlangen (DE) – 
HICC 5 27225 1.7 1.7 1.5-1.8 0.4 (0-1.1) Middlesbrough (UK) 4.7 (1.8-7.5) Göttingen (DE) – 
Formaldehyde* 1 19829 1.5 1.5 1.4-1.7 0 (0-1) Alicante (ES) 3.5 (0.6-6.4) León (ES)
TT
 0 (0–1) 
Formaldehyde* 2 9972 1.8 1.7 1.4-1.9 0 (0-1) Alicante (ES) 2.6 (2-3.2) London (UK) – 
Neomycin sulfate 20 23385 1.3 1.2 1.1-1.4 0 (several depts.) 10.9 (0-26.2) Kiel (DE)
D1
 1.6 (0.6–3.4) 
Epoxy resin 1 28577 1.1 1.1 1-1.2 0 (several depts.) 4.9 (0.2-9.5) Aarau (CH) 0 (0–1) 
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Tixocortol-pivalate 0.1 14130 0.5 0.5 0.4-0.6 0 (several depts.) 1 (0.4-1.7) Poznan (PL) 0.3 (0–1.5) 
Tixocortol-pivalate 1 8517 0.9 0.9 0.7-1.1 0 (0-0.6) Basel (CH) 1.4 (0.9-2) Amsterdam VU 
(NL) 
– 
Quaternium 15 1 18404 0.8 0.8 0.7-0.9 0 (several depts.) 2.9 (0.1-5.7) León (ES)
TT
 0.8 (0.2–2.3) 
Budesonide 0.01 12863 0.8 0.8 0.6-0.9 0 (several depts.) 2.4 (1.3-3.5) Poznan (PL) 0 (0–1) 
Budesonide 0.1 9009 0.4 0.3 0.2-0.5 0 (several depts.) 1 (0.3-1.7) Basel (CH) – 
Mercapto mix (CBS, MBTS, MOR) 1 9978 0.7 0.7 0.5-0.9 0.2 (0-0.5) Dresden (DE)
D1
 1.9 (0.4-3.4) Jena (DE) – 
Mercapto mix 
(MBT,CBS,MBTS,MOR) 
2 17664 0.7 0.7 0.6-0.8 0 (several depts.) 2.1 (0-5) Murcia (ES)
TT
 – 
Mercaptobenzothiazole 2 28618 0.6 0.6 0.5-0.7 0 (several depts.) 2.7 (0-5.8) Murcia (ES)
TT
 0.3 (0–1.5) 
Sesquiterpenlactone mix 0.1 13405 0.8 0.7 0.6-0.9 0 (several depts.) 1.2 (0.3-2.2) Cardiff (UK) – 
ptBFR 1 24743 0.7 0.7 0.6-0.8 0 (several depts.) 2.2 (1.1-3.3) Groningen 
(NL)
TT
 
0 (0–1) 
Benzocaine 5 13085 0.6 0.6 0.5-0.7 0 (several depts.) 1.8 (0.6-3.1) Vigo (ES) 0 (0–1) 
IPPD 0.1 24163 0.6 0.6 0.5-0.7 0 (several depts.) 1.8 (0.5-3) Erlangen (DE) 0 (0–1) 
Paraben mix 16 28569 0.5 0.5 0.4-0.6 0 (several depts.) 2.4 (0.6-4.1) Dresden (DE)
D1
 0 (0–1) 
Clioquinol 5 11922 0.3 0.3 0.2-0.4 0 (several depts.) 0.9 (0.2-1.6) 
Barcelona/IMAS (ES) 
– 
Primin 0.01 16517 0.2 0.2 0.2-0.3 0 (several depts.) 0.9 (0-2) Maribor/Clinic (SI) – 
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All allergens in petrolatum, except where indicated otherwise: * water  
TT: extreme prevalence (high or low, respectively) obtained with a TRUE test® allergen. 
D1: extreme prevalence (high or low, respectively) obtained with 1 day patch test exposure. 
MCI/MI, Methylchloroisothiazolinone Methylisothiazolinone; MDBGN, Methyldibromo glutaronitrile (dibromdicyanobutane); ptBFR, p-tert-
Butylphenol formaldehyde resin; IPPD, N-Isopropyl-N’-phenyl-p-phenylene diamine; HICC, hydroxyisohexyl 3-cyclohexene carboxaldehyde. 
 
Table 3: Patch test results with the European baseline series (14) obtained in ESSCA departments specialised in occupational dermatology (age- 
and sex-standardised prevalences). The maximum reading between day (D)3 and D5 (inclusive) was considered. In none of these departments 
had the TRUE test® been used. If under ‘minimum’ only one department’s name is shown, the results in the columns at the left refer to this 
department. 
 
 Conc. nr crude stand. 95% minimum maximum 
Hapten % (test) %(pos) %(pos.) CI stand. %(pos.) stand. %(pos.) 
Nickel sulfate 5 2388 19.1 21.7 19.9-23.4 8.6 (5.8-11.4) Osnabrück (DE) 32 (25.8-38.2) Łodz (PL) 
Methylisothiazolinone * 0.02 86 4.7 5 0-10.1 Łodz (PL) – 
Methylisothiazolinone * 0.05 535 9 8.2 5.7-10.8 7.5 (4.5-10.6) Osnabrück (DE) 9.3 (4.9-13.8) Heidelberg (DE) 
Methylisothiazolinone * 0.2 117 4.3 4.2 0.4-8.1 Łodz (PL) – 
Fragrance mix I 8 2433 6.7 6.4 5.4-7.3 3.7 (1.1-6.3) Helsinki (FI) 9.6 (6.6-12.7) Heidelberg (DE) 
MCI/MI * 0.01 2128 5 4.8 3.8-5.7 1.7 (0.7-2.6) Trieste (IT) 9.9 (6.8-12.9) Heidelberg (DE) 
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MCI/MI * 0.02 229 9.6 10.8 6.4-15.3 Helsinki (FI) – 
Cobalt chloride 1 2451 5.4 6 4.9-7 3.7 (1.2-6.3) Helsinki (FI) 13.9 (9-18.8) Łodz (PL) 
Myroxolon pereirae (Balsam of Peru) 25 2478 4.8 4.4 3.6-5.2 0.7 (0-2) Cádiz (ES) 6.7 (2.9-10.4) Łodz (PL) 
Fragrance mix II 14 1548 3.9 3.6 2.7-4.6 0.8 (0-2.5) łodz (PL) 4.9 (2.9-6.9) Heidelberg (DE) 
Potassium dichromate 0.5 2475 3.9 3.8 3-4.6 1.6 (0-3.3) Helsinki (FI) 8.2 (4.2-12.2) Łodz (PL) 
p-Phenylenediamine 1 1210 3.8 3.8 2.7-4.8 2.6 (0.6-4.8) Helsinki (FI) 4 (2.6-5.4) Trieste (IT) 
Colophonium 20 2484 2.7 2.4 1.8-3 0.7 (0.1-1.3) Trieste (IT) 4.4 (2.2-6.5) Heidelberg (DE) 
MDBGN 0.2 1148 3.5 2.8 1.8-3.8 1.2 (0.4-2.1) Osnabrück (DE) 4.8 (2.8-6.8) Heidelberg (DE) 
MDBGN 0.3 230 0.4 0.6 0-1.9 Helsinki (FI) – 
MDBGN 0.5 203 0.5 0.5 0-1.5 Łodz (PL) – 
Lanolin alcohol 30 2366 1.2 1.2 0.8-1.7 0.4 (0-0.7) Trieste (IT) 2.8 (several depts.) 
Thiuram mix 1 2458 3.1 2.9 2.2-3.6 1 (0-3) Cádiz (ES) 5.1 (3-7.1) Heidelberg (DE) 
HICC 5 1353 1.6 1.5 0.8-2.2 0 (0-1.5) łodz (PL) 2.5 (0.7-4.2) Heidelberg (DE) 
Formaldehyde * 1 2407 1.8 1.8 1.2-2.3 0 (0-2.5) Łodz (PL) 6.9 (3.4-10.4) Helsinki (FI) 
Formaldehyde * 2 83 7.2 7.9 1.4-14.3 Łodz (PL) – 
Neomycin sulfate 20 1334 1.6 1.5 0.8-2.1 0 (0-2.4) Cádiz (ES) 4 (0.9-7) Łodz (PL) 
Epoxy resin 1 2354 1.9 1.8 1.2-2.3 0.2 (0-0.6) Trieste (IT) 5.5 (2.4-8.6) Helsinki (FI) 
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Tixocortol-pivalate 0.1 435 1.8 1.9 0.6-3.1 1.3 (0-3) Helsinki (FI) 3.1 (0.5-5.7) Łodz (PL) 
Quaternium 15 1 1333 0.8 0.8 0.3-1.3 0.1 (0-0.3) Trieste (IT) 2.5 (0-5) Łodz (PL) 
Budesonide 0.01 203 1 0.7 0-1.7 Łodz (PL) – 
Budesonide 0.1 353 0.6 0.7 0-1.6 0 (0-2.4) Cádiz (ES) 1.2 (0-2.8) Helsinki (FI) 
Mercapto mix (CBS, MBTS, MOR) 1 2274 0.8 0.8 0.4-1.2 0 (0-1.3) Helsinki (FI) 1.9 (0.4-3.4) Heidelberg (DE) 
Mercapto mix (MBT,CBS,MBTS,MOR) 2 203 0 0 0-1.5 Łodz (PL) – 
Mercaptobenzothiazole 2 2483 0.7 0.7 0.4-1 0 (several depts.) 1.4 (0.3-2.6) Heidelberg (DE) 
Sesquiterpenlactone mix 0.1 324 0 0 0-0.9 0 (several depts.) – 
ptBFR 1 1857 0.4 0.4 0.1-0.7 0 (0-0.8) Osnabrück (DE) 1.4 (0-3.4) Łodz (PL) 
Benzocaine 5 1102 0.6 0.6 0.1-1.1 0.6 (0-1.1) Trieste (IT) 0.8 (0-2.4) Cádiz (ES) 
IPPD 0.1 1474 1.2 1 0.5-1.5 0.8 (0-2.4) Cádiz (ES) 1.2 (0.3-2.1) Osnabrück (DE) 
Paraben mix 16 2249 0.4 0.3 0.1-0.6 0 (0-2.4) Cádiz (ES) 0.7 (0-1.7) Łodz (PL) 
Clioquinol 5 324 0 0 0-0.9 0 (several depts.) – 
Primin 0.01 1334 0.1 0.1 0-0.3 0 (several depts.) 0.4 (0-1.1) Łodz (PL) 
All allergens in petrolatum, except where indicated otherwise:  water  
maximum ‘–’: tested only in one department (see ‘minimum’)  
MCI/MI, Methylchloroisothiazolinone Methylisothiazolinone; MDBGN, Methyldibromo glutaronitrile (dibromdicyanobutane); ptBFR, p-tert-
Butylphenol formaldehyde resin; IPPD, N-Isopropyl-N’-phenyl-p-phenylene diamine; HICC, hydroxyisohexyl 3-cyclohexene carboxaldehyde. 
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